After a lengthy approval process, the U.S. Food and Drug Administration (FDA) has finally approved Revance’s highly anticipated daxibotulinumtoxinA, now called Daxxify. The neuromodulators currently available (Botox, Dysport, Xeomin, Jeuveau) tend to last three to four months, whereas in FDA trials, the median duration of Daxxify was six months. But it is important to note that Daxxify's FDA approval is only for injection into the glabellar lines as of now. Also noteworthy: Unlike its counterparts, Daxxify does not contain human albumin, a stabilizing protein. It’s considered vegan and “cleaner” than alternative treatments.

We will be adding Daxxify to our treatment list when it becomes available, for the clinets that love the effects of botulinum toxins but often complain that they wear off too quickly.